Literature DB >> 16311354

Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses.

N T van Heek1, S J Clayton, P D J Sturm, J Walker, D J Gouma, L A Noorduyn, G J A Offerhaus, J C Fox.   

Abstract

BACKGROUND: Extrahepatic biliary stenosis (EBS) has malignant and benign causes. Patients with EBS are at risk of having or developing malignancy. Accurate diagnostic tests for early detection and surveillance are needed. The sensitivity of biliary cytology for malignancy is low. K-ras mutation analysis on brush cytology is a valuable adjunct, but specificity is low. A quantitative test for K-ras mutations has been developed: the amplification refractory mutation system (ARMS). AIM: To assess the test characteristics and additional value of ARMS in diagnosing the cause of EBS.
METHODS: Brush samples from endoscopic retrograde cholangiopancreatography were collected from 312 patients with EBS. K-ras mutation analysis was performed using ARMS-allele specific amplification was coupled with real time fluorescent detection of PCR products. Results were compared with conventional cytology and K-ras mutation analysis using allele specific oligonucleotide (ASO) hybridisation, and evaluated in view of the final diagnosis.
RESULTS: The test characteristics of ARMS and ASO largely agreed. Sensitivity for detecting malignancy was 49% and 42%, specificity 93% and 88%, and positive predictive value (PPV) 96% and 91%, respectively. The sensitivity of ARMS and cytology combined was 71%, and PPV was 93%. The specificity of ARMS could be increased to 100% by setting limits for the false positives, but reduced sensitivity from 49% to 43%.
CONCLUSIONS: ARMS can be considered supplementary to conventional cytology, and comparable to ASO in diagnosing malignant EBS. A specificity of 100% can be achieved with ARMS, which should be considered in the surveillance of patients at risk for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311354      PMCID: PMC1770790          DOI: 10.1136/jcp.2004.022707

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  47 in total

Review 1.  Progression model for pancreatic cancer.

Authors:  R H Hruban; M Goggins; J Parsons; S E Kern
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

2.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

3.  K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification.

Authors:  S J Clayton; F M Scott; J Walker; K Callaghan; K Haque; T Liloglou; G Xinarianos; S Shawcross; P Ceuppens; J K Field; J C Fox
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

Review 4.  Cancer surveillance of patients from familial pancreatic cancer kindreds.

Authors:  T A Brentnall
Journal:  Med Clin North Am       Date:  2000-05       Impact factor: 5.456

5.  Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer.

Authors:  T Suto; W Habano; T Sugai; N Uesugi; O Funato; S Kanno; K Saito; S i Nakamura
Journal:  J Surg Oncol       Date:  2000-03       Impact factor: 3.454

6.  Diagnostic value of brush cytology in the diagnosis of duodenal, biliary, and ampullary neoplasms.

Authors:  R H Bardales; M W Stanley; D D Simpson; S J Baker; C T Steele; R F Schaefer; C N Powers
Journal:  Am J Clin Pathol       Date:  1998-05       Impact factor: 2.493

7.  Progress in determining the nature of bile duct strictures.

Authors:  B R Davidson
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

8.  Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.

Authors:  A C Tersmette; G M Petersen; G J Offerhaus; F C Falatko; K A Brune; M Goggins; E Rozenblum; R E Wilentz; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

9.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.

Authors:  Christine A Iacobuzio-Donahue; Anirban Maitra; Grace L Shen-Ong; Tjarda van Heek; Raheela Ashfaq; Renee Meyer; Kimberly Walter; Karin Berg; Michael A Hollingsworth; John L Cameron; Charles J Yeo; Scott E Kern; Michael Goggins; Ralph H Hruban
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

10.  Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene.

Authors:  K Motojima; T Tsunoda; T Kanematsu; Y Nagata; T Urano; H Shiku
Journal:  Ann Surg       Date:  1991-12       Impact factor: 12.969

View more
  5 in total

Review 1.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

2.  Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.

Authors:  Benjamin R Kipp; Emily G Barr Fritcher; Amy C Clayton; Gregory J Gores; Lewis R Roberts; Jun Zhang; Michael J Levy; Kevin C Halling
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

3.  Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Authors:  Fotios Loupakis; Chiara Cremolini; Gabriella Fontanini; Irene Stasi; Lisa Salvatore; Alfredo Falcone
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

4.  Fast simultaneous detection of K-RAS mutations in colorectal cancer.

Authors:  Ya-Sian Chang; Kun-Tu Yeh; Tien-Jye Chang; Connie Chai; Hsiu-Chin Lu; Nicholas C Hsu; Jan-Gowth Chang
Journal:  BMC Cancer       Date:  2009-06-11       Impact factor: 4.430

Review 5.  Computational and experimental approaches to reveal the effects of single nucleotide polymorphisms with respect to disease diagnostics.

Authors:  Tugba G Kucukkal; Ye Yang; Susan C Chapman; Weiguo Cao; Emil Alexov
Journal:  Int J Mol Sci       Date:  2014-05-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.